-
1
Neolithic introgression of IL23R-related protection against chronic inflammatory bowel diseases in modern EuropeansResearch in context
Published 2025-03-01Subjects: “…IL23R…”
Get full text
Article -
2
Dysbiosis of the human skin mycobiome in patients receiving systemic IL-23 inhibitors
Published 2025-01-01Subjects: Get full text
Article -
3
Assessment of The Impact of Apremilast on Levels of IL-17, IL-23, and Lipids in Obese Psoriatic Patient
Published 2024-12-01Subjects: Get full text
Article -
4
Safety of interleukin inhibitors in patients with plaque psoriasis and history of neoplasms: a multicenter retrospective study – IL PSO (Italian landscape psoriasis)
Published 2025-12-01Subjects: “…Anti-IL-23…”
Get full text
Article -
5
Diagnostic value of interleukins 23 and 17 in the assessment of ulcerative colitis severity
Published 2024-12-01Subjects: Get full text
Article -
6
Portuguese consensus on first line treatment of moderate-to-severe psoriasis with a non-TNF inhibitor therapy – a delphi methodology
Published 2025-12-01Subjects: Get full text
Article -
7
Breakthrough Psoriasis in Patients Receiving Biologicals
Published 2025-01-01Subjects: Get full text
Article -
8
Evaluation of Interleukin-23 and Creatine Kinase –MB (CK-MB) Levels in Acute Coronary Syndrome Patients with COVID-19 in Baghdad City
Published 2022-11-01Subjects: Get full text
Article -
9
黄芩多糖通过调节JAK2/STAT3通路和IL-23/IL-17炎性轴改善DSS诱导的UC模型小鼠的炎症
Published 2023-05-01Subjects: Get full text
Article -
10
Enhanced antitumor efficacy of STING agonist MSA-2 by lipid nanoparticles delivering circular IL-23 mRNA and platinum-modified MSA-2 combination
Published 2025-02-01Subjects: Get full text
Article